Abbott Laboratories Reports Strong Cardiovascular Device Trial Data at TCT Conference

Abbott Laboratories presented positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference in San Diego on November 2. The company reported high procedural success rates and low complication rates for devices targeting patients with irregular heart rhythms and severely calcified coronary arteries. One-year data for Abbott's next-generation Amulet 360 device showed high rates of left atrial appendage closure and a low incidence of stroke, reinforcing the device's potential as a treatment for patients at risk of stroke from atrial fibrillation.

On the distribution side, HSS Medical Supply announced a new distributor agreement for Abbott's ID NOW rapid molecular testing platform, expanding the reach of that point-of-care diagnostics tool. Abbott operates in a rapid microbiological testing market projected to reach $10 billion globally by 2030, alongside competitors including bioMerieux, Bio-Rad, and Becton Dickinson.

In a separate disclosure, Senator Thomas H. Kean Jr. reported selling shares of Abbott Laboratories while purchasing shares of ESAB, according to a Form 4 filing dated November 2. Abbott shares have recovered significantly from their 52-week low, trading up approximately 30% from that level as of November 2, though that gain trails several larger healthcare peers including Humana, up 154%, and DaVita, up 86%, over the same stretch.